Multinationals Return To Growth In China In First Half

New Drugs More Than Offset VBP Impact

AZ and Novo Nordisk reported sales growth from innovative new drugs in China, despite the lingering impact of the country's volume-based procurement scheme. Meanwhile, Novartis, Sanofi and Roche saw gains for new antibody and cancer drugs, along with solid vaccine sales.

Poring Studio/Shutterstock.com
Multinational drug makers return to growth in first half of 2023

AstraZeneca PLC, which is more reliant on the Chinese market than its multinational peers in terms of share of China-derived revenue within the total, sees its China business as on track for a return to growth, despite price reductions resulting from the country’s drug price negotiation since March.

In the first half ended 30 June, the UK-based major’s China sales rose 7% year-over-year to $3.0bn, accounting for 14%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia